and in survivors of acute lymphoblastic leukemia, where they were associated with cognitive late effects. Diagnosis SCT is currently not an official diagnosis in DSM-5 and no universally accepted set of symptoms exists yet. But there are rating scales that can be used to screen for SCT symptoms such as the Concentration Inventory (for children and adults) or the Barkley Sluggish Cognitive Tempo Scale-Children and Adolescents (BSCTS-CA). The Comprehensive Behaviour Rating Scale for Children (CBRSC), an older scale, can also be used for SCT as this case study shows. Additional requirements for a proposed SCT diagnosis (such as the number and duration of symptoms or the impact on functioning) are continuing to be investigated. Although having no diagnostic code either, ICD-10 mentions the SCT group as a reason for why it did not replace the term "Hyperkinetic Disorder" with "ADHD". Other mental disorders may produce similar symptoms to SCT (e.g. excessive daydreaming or "staring blankly") and should not be confused with it. Examples might be conditions like depersonalization disorder, dysthymia, thyroid problems, absence seizures, Bipolar II disorder, Kleine–Levin syndrome, forms of autism or schizoid personality disorder. However, the prevalence of SCT in these clinical populations has yet to be empirically and systematically investigated. Treatment Treatment of SCT has not been well investigated. Initial drug studies were done only with the ADHD medication methylphenidate (e.g. Ritalin®), and even then only with children who were diagnosed as ADD without hyperactivity (using DSM-III criteria) and not specifically for SCT. The research seems to have found that most children with ADD (attention deficit disorder) with Hyperactivity (currently ADHD combined type) responded well at medium-to-high doses. However, a sizable percentage of children with ADD without hyperactivity (currently ADHD inattentive type, therefore the results may apply to SCT) did not gain much benefit from methylphenidate, and when they did benefit, it was at a much lower dose. However, one study and a retrospective analysis of medical histories found that the presence or absence of SCT symptoms made no difference in response to methylphenidate in children with ADHD-I. But these studies did not specifically and explicitly examine the effect of the drug on SCT symptoms in children. The medication studies who did this found atomoxetine (Strattera) to have significant beneficial effects that were independent of ADHD symptoms and a poor response for methylphenidate. Only one study has investigated the use of behavior modification methods at home and